CLL

clinical topic updates

by Jennifer R. Brown, MD, PhD

Advances in the understanding of the pathobiology of chronic lymphocytic leukemia (CLL) have led to the success of targeted therapies such as Bruto......READ MORE

clinical topic updates

by Susan O’Brien, MD

The BCL-2 inhibitor venetoclax has an established role in the treatment of chronic lymphocytic leukemia (CLL), but its utilization in the community......READ MORE

patient care perspectives

by Susan O’Brien, MD

Many patients with newly diagnosed chronic lymphocytic leukemia (CLL) do not require treatment initially, and some may never require treatment at a......READ MORE

expert roundtables

by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD

Chronic lymphocytic leukemia (CLL) treatment can impact quality of life (QOL) in many different ways. Psychological aspects of treatment may be imp......READ MORE

expert roundtables

by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD

Our featured experts describe the latest data that guide decisions on initial therapy for the treatment of chronic lymphocytic leukemia (CLL). Incr......READ MORE